NHL: Follicular Lymphoma Forecast and Market Analysis to 2025

  • ID: 3797464
  • Drug Pipelines
  • 229 pages
  • Datamonitor Healthcare
1 of 3
Follicular lymphoma (FL) is an indolent subtype of non-Hodgkin’s lymphoma (NHL). It is the second most common type of NHL after diffuse large B-cell lymphoma (DLBCL), and accounts for more than 20% of all NHL cases. The disease is staged based on the percentage of large cells occurring within the malignant B lymphocytes. Low grades of FL are generally characterized by slow progression of the disease. Patients can be managed successfully to prolong remission times and extend survival, but the disease is mostly incurable. In contrast, higher grades of FL tend to become more aggressive in nature and require timely treatment.

Recent events and opinion
  • New and recent drug launches will compensate for biosimilar and generic erosion of current leading brands.
  • For most FL patients, both in localized stage and bulky stage, combinations featuring Rituxan are among the most common regimens prescribed.
  • Incident cases of the three major subtypes of NHL will increase by at least a quarter over the forecast period.
  • Rituxan’s dominance in the market faces threats from upcoming biosimilar competition and from the third-generation monoclonal antibody Gazyva.
  • Late-stage drugs in development potentially satisfy the need for more second-line Rituxan-refractory follicular lymphoma therapies.
Note: Product cover images may vary from those shown
2 of 3
Table of Contents (Forecast, Treatment, Epidemiology Datapacks included)
FORECAST: FOLLICULAR LYMPHOMA (Published on 15 April 2016)
OVERVIEW
EXECUTIVE SUMMARY
MARKET OVERVIEW AND TRENDS
METHODOLOGY AND MARKET DEFINITION
COPANLISIB
DUVELISIB
GAZYVA (OBINUTUZUMAB)
IMBRUVICA (IBRUTINIB)
REVLIMID (LENALIDOMIDE)
RITUXAN (RITUXIMAB)
TREANDA (BENDAMUSTINE)
ZEVALIN (IBRITUMOMAB TIUXETAN)
ZYDELIG (IDELALISIB)
PRIMARY RESEARCH METHODOLOGY

TREATMENT: FOLLICULAR LYMPHOMA (Published on 15 April 2016)
OVERVIEW
EXECUTIVE SUMMARY
PRIMARY RESEARCH METHODOLOGY
DISEASE DEFINITION AND DIAGNOSIS
PATIENT SEGMENTATION
COUNTRY TREATMENT TREES
CURRENT TREATMENT OPTIONS
PRESCRIBING TRENDS

EPIDEMIOLOGY: FOLLICULAR LYMPHOMA (Published on 11 April 2018)
OVERVIEW
DISEASE BACKGROUND
METHODOLOGY
FORECAST
BIBLIOGRAPHY
APPENDIX: ADDITIONAL SOURCES

MARKETED DRUGS: FOLLICULAR LYMPHOMA (Published on 15 March 2016)
OVERVIEW
EXECUTIVE SUMMARY
PRODUCT OVERVIEW
PRODUCT PROFILE: GAZYVA
PRODUCT PROFILE: RITUXAN
PRODUCT PROFILE: TREANDA
PRODUCT PROFILE: ZEVALIN
PRODUCT PROFILE: ZYDELIG

PIPELINE: FOLLICULAR LYMPHOMA (Published on 15 March 2016)
OVERVIEW
EXECUTIVE SUMMARY
CLINICAL PIPELINE OVERVIEW
PRODUCT PROFILE (LATE STAGE): ARZERRA
PRODUCT PROFILE (LATE STAGE): IMBRUVICA
PRODUCT PROFILE (LATE STAGE): REVLIMID
PRODUCT PROFILE (LATE STAGE): COPANLISIB
PRODUCT PROFILE (LATE STAGE): DUVELISIB

List of Figures
Figure 1: Follicular lymphoma drug sales in the US, Japan, and five major EU markets, by status ($m), 2016-25
Figure 2: Follicular lymphoma drug sales in the US, by status ($m), 2016-25
Figure 3: Follicular lymphoma drug sales in Japan, by status ($m), 2016-25
Figure 4: Follicular lymphoma drug sales in the five major EU markets, by status ($m), 2016-25
Figure 5: Patient-based forecast methodology for follicular lymphoma
Figure 6: Price sources and calculations, by country
Figure 7: Copanlisib sales for follicular lymphoma in the US, Japan, and five major EU markets, by country ($m), 2016-25
Figure 8: Duvelisib sales for follicular lymphoma in the US, Japan, and five major EU markets, by country ($m), 2016-25
Figure 9: Gazyva sales for follicular lymphoma in the US, Japan, and five major EU markets, by country ($m), 2016-25
Figure 10: Imbruvica sales for follicular lymphoma in the US, Japan, and five major EU markets, by country ($m), 2016-25
Figure 11: Revlimid sales for follicular lymphoma in the US, Japan, and five major EU markets, by country ($m), 2016-25
Figure 12: Rituxan sales for follicular lymphoma in the US, Japan, and five major EU markets, by country ($m), 2016-25
Figure 13: Treanda sales for follicular lymphoma in the US, Japan, and five major EU markets, by country ($m), 2016-25
Figure 14: Zevalin sales for follicular lymphoma in the US, Japan, and five major EU markets, by country ($m), 2016-25
Figure 15: Zydelig sales for follicular lymphoma in the US, Japan, and five major EU markets, by country ($m), 2016-25
Figure 16: Proportion of follicular lymphoma diagnosed at localized and bulky stages of disease, by country (%), 2016
Figure 17: Proportion of localized-stage (I/II) patients in each treatment category, by country (%), 2016
Figure 18: Proportion of localized-stage (I/II) patients receiving each treatment type, by country (%), 2016
Figure 19: Proportions of localized-stage (I/II) follicular lymphoma patients receiving first-line induction therapies, by country (%), 2016
Figure 20: Proportions of localized-stage (I/II) follicular lymphoma patients receiving first-line maintenance therapies, by country (%), 2016
Figure 21: Proportions of localized-stage (I/II) follicular lymphoma patients receiving second-line therapies, by country (%), 2016
Figure 22: Proportions of localized-stage (I/II) follicular lymphoma patients receiving second-line maintenance therapies, by country (%), 2016
Figure 23: Proportions of localized-stage (I/II) follicular lymphoma patients receiving third-line therapies, by country (%), 2016
Figure 24: Proportions of localized-stage (I/II) follicular lymphoma patients receiving third-line maintenance therapies, by country (%), 2016
Figure 25: Proportion of bulky-stage (II/III/IV) patients in each treatment category, by country (%), 2016
Figure 26: Proportion of bulky-stage (II/III/IV) patients receiving each treatment type, by country (%), 2016
Figure 27: Proportions of bulky-stage (II/III/IV) follicular lymphoma patients receiving first-line induction therapies, by country (%), 2016
Figure 28: Proportions of bulky-stage (II/III/IV) follicular lymphoma patients receiving first-line maintenance therapies, by country (%), 2016
Figure 29: Trends in incident cases of NHL in the US, Japan, and five major EU markets, 2017-37
Figure 30: Trends in incident cases of DLBCL in the US, Japan, and five major EU markets, 2017-37
Figure 31: Trends in incident cases of FL in the US, Japan, and five major EU markets, 2017-37
Figure 32: Trends in incident cases of MCL in the US, Japan, and five major EU markets, 2017-37
Figure 33: Drug assessment overview in follicular lymphoma
Figure 34: Gazyva for follicular lymphoma - SWOT analysis
Figure 35: Drug assessment summary of Gazyva in follicular lymphoma
Figure 36: Drug assessment summary for Gazyva in follicular lymphoma
Figure 37: Rituxan for follicular lymphoma - SWOT analysis
Figure 38: Drug assessment summary of Rituxan in follicular lymphoma
Figure 39: Drug assessment summary for Rituxan in follicular lymphoma
Figure 40: Treanda for follicular lymphoma - SWOT analysis
Figure 41: Drug assessment summary of Treanda in follicular lymphoma
Figure 42: Drug assessment summary for Treanda in follicular lymphoma
Figure 43: Zevalin for follicular lymphoma - SWOT analysis
Figure 44: Drug assessment summary of Zevalin in follicular lymphoma
Figure 45: Drug assessment summary for Zevalin in follicular lymphoma
Figure 46: Zydelig for follicular lymphoma - SWOT analysis
Figure 47: Drug assessment summary of Zydelig in follicular lymphoma
Figure 48: Drug assessment summary for Zydelig in follicular lymphoma
Figure 49: Arzerra for follicular lymphoma - SWOT analysis
Figure 50: Drug assessment summary of Arzerra in follicular lymphoma
Figure 51: Drug assessment summary for Arzerra in follicular lymphoma
Figure 52: Imbruvica for follicular lymphoma - SWOT analysis
Figure 53: Drug assessment summary of Imbruvica in follicular lymphoma
Figure 54: Drug assessment summary for Imbruvica in follicular lymphoma
Figure 55: Revlimid for follicular lymphoma - SWOT analysis
Figure 56: Drug assessment summary of Revlimid in follicular lymphoma
Figure 57: Drug assessment summary for Revlimid in follicular lymphoma
Figure 58: Copanlisib for follicular lymphoma - SWOT analysis
Figure 59: Drug assessment summary of copanlisib in follicular lymphoma
Figure 60: Drug assessment summary for copanlisib in follicular lymphoma
Figure 61: Duvelisib for follicular lymphoma - SWOT analysis
Figure 62: Drug assessment summary of duvelisib in follicular lymphoma
Figure 63: Drug assessment summary for duvelisib in follicular lymphoma

List of Tables
Table 1: Follicular lymphoma drug sales in the US, Japan, and five major EU markets, by brand ($m), 2016-25
Table 2: Follicular lymphoma drug sales in the US, by brand ($m), 2016-25
Table 3: Follicular lymphoma drug sales in Japan, by brand ($m), 2016-25
Table 4: Follicular lymphoma drug sales in the five major EU markets, by brand ($m), 2016-25
Table 5: Summary of drug classes and molecules in the author’s follicular lymphoma patient-based forecast
Table 6: Exchange rates used for calculating prices
Table 7: Patent expiry dates for key marketed brands in follicular lymphoma in the US, Japan, and five major EU markets, 2016-25
Table 8: The author’s estimated launch dates of key late-stage pipeline products and marketed brands in follicular lymphoma, 2016-25
Table 9: Copanlisib sales for follicular lymphoma in the US, Japan, and five major EU markets, by country ($m), 2016-25
Table 10: Copanlisib patient numbers for follicular lymphoma in the US, Japan, and five major EU markets, by country, 2016-25
Table 11: Duvelisib sales for follicular lymphoma in the US, Japan, and five major EU markets, by country ($m), 2016-25
Table 12: Duvelisib patient numbers for follicular lymphoma in the US, Japan, and five major EU markets, by country, 2016-25
Table 13: Gazyva sales for follicular lymphoma in the US, Japan, and five major EU markets, by country ($m), 2016-25
Table 14: Gazyva patient numbers for follicular lymphoma in the US, Japan, and five major EU markets, by country, 2016-25
Table 15: Imbruvica sales for follicular lymphoma in the US, Japan, and five major EU markets, by country ($m), 2016-25
Table 16: Imbruvica patient numbers for follicular lymphoma in the US, Japan, and five major EU markets, by country, 2016-25
Table 17: Revlimid sales for follicular lymphoma in the US, Japan, and five major EU markets, by country ($m), 2016-25
Table 18: Revlimid patient numbers for follicular lymphoma in the US, Japan, and five major EU markets, by country, 2016-25
Table 19: Rituxan sales for follicular lymphoma in the US, Japan, and five major EU markets, by country ($m), 2016-25
Table 20: Rituxan patient numbers for follicular lymphoma in the US, Japan, and five major EU markets, by country, 2016-25
Table 21: Treanda sales for follicular lymphoma in the US, Japan, and five major EU markets, by country ($m), 2016-25
Table 22: Treanda patient numbers for follicular lymphoma in the US, Japan, and five major EU markets, by country, 2016-25
Table 23: Zevalin sales for follicular lymphoma in the US, Japan, and five major EU markets, by country ($m), 2016-25
Table 24: Zevalin patient numbers for follicular lymphoma in the US, Japan, and five major EU markets, by country, 2016-25
Table 25: Zydelig sales for follicular lymphoma in the US, Japan, and five major EU markets, by country ($m), 2016-25
Table 26: Zydelig patient numbers for follicular lymphoma in the US, Japan, and five major EU markets, by country, 2016-25
Table 27: Physicians surveyed for the follicular lymphoma primary research study, 2016
Table 28: Physicians surveyed for the follicular lymphoma primary research study, 2016
Table 29: Five- and ten-year observed survival rates for follicular lymphoma
Table 30: Ann Arbor stage classification
Table 31: Revised staging system for primary nodal lymphomas
Table 32: Targeted drugs for the treatment of follicular lymphoma
Table 33: Main cytotoxic therapies for the treatment of follicular lymphoma
Table 34: Cancer registry databases used as a source of NHL, DLBCL, FL, and MCL incidence data, by country
Table 35: Ann Arbor classification system
Table 36: Incident cases of NHL in the US, Japan, and five major EU markets, 2017-37
Table 37: Incident cases of DLBCL in the US, Japan, and five major EU markets, 2017-37
Table 38: Incident cases of FL in the US, Japan, and five major EU markets, 2017-37
Table 39: Incident cases of MCL in the US, Japan, and five major EU markets, 2017-37
Table 40: Key marketed drugs for follicular lymphoma
Table 41: Gazyva drug profile
Table 42: Clinical development of Gazyva in follicular lymphoma
Table 43: Gazyva Phase II data in relapsed follicular lymphoma
Table 44: Rituxan drug profile
Table 45: Overview of pivotal trial data for Rituxan in follicular lymphoma
Table 46: Subcutaneous administration of Rituxan in follicular lymphoma
Table 47: Treanda drug profile
Table 48: Overview of pivotal trial data for Treanda in follicular lymphoma
Table 49: Data for first-line therapy trial for Treanda in follicular lymphoma
Table 50: Zevalin drug profile
Table 51: Overview of pivotal trial data for Zevalin in follicular lymphoma
Table 52: Zydelig drug profile
Table 53: Overview of pivotal trial data for Zydelig in follicular lymphoma
Table 54: Phase III pipeline products in development for follicular lymphoma
Table 55: Compounds that were recently discontinued in follicular lymphoma
Table 56: Arzerra - drug profile
Table 57: Clinical development of Arzerra in follicular lymphoma
Table 58: Phase II data: Arzerra plus Treanda as first-line therapy in follicular lymphoma
Table 59: Imbruvica - drug profile
Table 60: Clinical development of Imbruvica in follicular lymphoma
Table 61: Phase II data: Imbruvica in combination with Rituximab in treatment-naïve follicular lymphoma patients
Table 62: Revlimid - drug profile
Table 63: Clinical development of Revlimid in follicular lymphoma
Table 64: Phase II data: Revlimid in combination with Rituxan as first-line therapy in CD20-positive follicular lymphoma patients
Table 65: Copanlisib - drug profile
Table 66: Clinical development of copanlisib in follicular lymphoma
Table 67: Phase IIb data: copanlisib as monotherapy in relapsed follicular lymphoma patients
Table 68: Duvelisib - drug profile
Table 69: Clinical development of duvelisib in follicular lymphoma
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll